<DOC>
	<DOCNO>NCT01117233</DOCNO>
	<brief_summary>The purpose study safety , tolerability , pharmacokinetics pharmacodynamics PF-04427429 administer intravenously healthy adult volunteer</brief_summary>
	<brief_title>Study In Healthy Adult Volunteers To Evaluate The Safety , Tolerability , Pharmacokinetics And Pharmacodynamics Of PF-04427429</brief_title>
	<detailed_description />
	<criteria>Healthy male subject age 18 50 year inclusive ( unless local regulation dictate minimum age 21 year ) . Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight 50 kg 100 kg inclusive . Evidence personally sign date informed consent document indicate subject ( legally acceptable representative ) inform pertinent aspect trial . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , genitourinary , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , symptomatic , seasonal allergy time dose ) . Any condition possibly affect drug absorption . 12lead ECG demonstrate QTcF &gt; 450 msec Screening . If QTcF exceed 450 msec , ECG repeat two time average three QTcF value use determine subject 's eligibility .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>PK</keyword>
	<keyword>PD</keyword>
	<keyword>safety toleration</keyword>
</DOC>